Testosterone Blood Clot Warnings Added for DVT, Pulmonary Embolism

Federal drug regulators are requiring the manufacturers of AndroGel, Testim, Axiron, Depo-Testosterone and others “Low T” drugs to add new warnings about the link between blood clots and testosterone replacement therapy, including an increased risk of deep vein thrombosis (DVT) or pulmonary embolism.

On June 19, the FDA indicated that additional information about the risk of blood clots will be added to testosterone drug labels, indicating that the medications may cause venous thromboembolism (VTE).

The statement comes as the FDA continues to investigate the potential link between testosterone and heart problems, following studies earlier this year that suggested men using the “Low T” drugs may face an increased risk of heart attacks, strokes and death.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Side effects of testosterone therapy were already known to increase the risk of blood clots due to a problem called polycythemia, an abnormal increase in red blood cells. However, the FDA now reports that it has found reports of blood clots above and beyond those linked to polycythemia. The new label warning changes the existing blood clot warning from one linking the problem to polycythemia, to a more generalized VTE warning.

Venous thromboembolism are blood clots that occur in the veins. They can lead to painful clots in the legs, known as deep vein thrombosis (DVT), or they can break off and flow to the heart and lungs, resulting in a pulmonary embolism, which can sometimes be deadly.

The FDA warning notes that these blood clots appear to be a different problem than those that may be causing testosterone users to suffer heart attacks and strokes.

An investigation into the cardiovascular risks associated with testosterone drugs was launched by the FDA on January 31, following at least two studies that raised concerns about the safety of the widely used and aggressively promoted medications.

In November 2013, a study published in the Journal of the American Medical Association (JAMA) found that certain men with pre-existing heart problems may face an increased risk of heart attacks, strokes and death from testosterone drugs.

That research was followed by a study published in the medical journal PLOSOne in January 2014, which found that side effects of low T treatments may double the risk of heart attack for younger men with heart disease and men over the age of 65, regardless of their prior heart conditions.

Following the studies and the launch of the FDA investigation, a growing number of AndroGel lawsuits, AndroDerm lawsuits, Testim lawsuits, Axiron lawsuits and other products have been filed by men throughout the United States, alleging that inadequate warnings were provided about the risk of heart attack, stroke, pulmonary embolism, deep vein thrombosis and wrongful death.

Most of the lawsuits filed to date have involved injuries associated with the use of AndroGel, which is the most widely used testosterone gel spray manufactured and sold by AbbVie. However, earlier this month a panel of federal judges consolidated all testosterone drug lawsuits filed in federal courts nationwide into the Northern District of Illinois for pretrial proceedings as part of a testosterone NDL, or multidistrict litigation.

1 Comments

  • richardJuly 23, 2014 at 9:53 am

    Companys really should do more reasearch before trying on the human population!

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted 2 days ago)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 4 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.